Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases

Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases

Background Toll-like receptor 9 (TLR9) agonists induce inflammatory responses that promote the killing of infectious micro-organisms, cancer cells and develop adaptive immune responses. Their ability as immunomodulators to enhance the activity of checkpoint inhibitors (CPI) in treating liver tumors...

Full description

Saved in:
Bibliographic Details
Main Authors: Diwakar Davar, Yujia Liu, Jason Laporte, Prajna Guha, Steven C Katz, Chandra C Ghosh, Lauren Cournoyer, Alizee Ballarin, Ilan B Layman, Molly Morrissey, Kayla Fraser, Shriya Perati, Bryan F Cox, Evgeny Yakirevich, Diana O Treaba, Timothy D Murtha
Format: Article
Language:English
Published: BMJ Publishing Group 2024-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/12/7/e008837.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/12/7/e008837.full

Similar Items